Business Wire

Biognosys to Present Major Scientific and Technological Advances at the ASMS 2021 Mass Spectrometry Conference

Share

Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, today announced they will be presenting major scientific and technological advances on their proprietary proteomics research services, software, and kits at the American Society for Mass Spectrometry (ASMS) Annual Conference from October 31st to November 4th in Philadelphia (USA).

Biognosys will present a record number of 3 oral presentations, 10 scientific posters, 2 poster collaborations, 1 workshop panel, and 2 Spectronaut™ breakfast seminars. In addition, their team of scientific experts will be present at booth #224 to answer questions and demo software. Further demo sessions will be offered at the Bruker Daltonics booth #719.

Collectively, this presence demonstrates Biognosys’ significant contributions to transforming life science and clinical research with next-generation proteomics, particularly in the areas of plasma proteomics, immunopeptidomics, and proteomics data analysis.

Lukas Reiter, PhD, Chief Technology Officer of Biognosys:
“Our major contribution to the ASMS scientific program is a testimony of Biognosys’ relentless commitment to innovation in mass spectrometry-based proteomics and progress in life science and clinical research.”

Discovering biomarkers in cancer with next-generation plasma proteomics

The plasma proteome is an underexplored source of insights on the health state of an individual. Biognosys will present results from a deep human plasma profiling study on a cohort of 180 lung, breast, colorectal, pancreatic, and prostate cancer patients, using an early version of their next-generation Plasma Biomarker Discovery workflow, launching in November. The workflow is optimized for use on Thermo Fisher Scientific Exploris 480 and FAIMS Pro instruments. Out of the entire plasma proteome, they quantified over 2,700 proteins and identified a protein panel with a significant positive predictive value for individual cancer stages.

Andreas Huhmer, Senior Director Life Sciences Research OMICS Marketing at Thermo Fisher Scientific:
“Biognosys has a proven track record for maximizing all innovative features of the Thermo Scientific™ Orbitrap™ mass spectrometers in state-of-the-art proteome analysis. Their new Plasma Biomarker Discovery workflow is a good example of this. The unprecedented depth and quantitative precision they can achieve, coupled with the inherently unbiased nature of mass spectrometry-based analysis, has the potential to take plasma biomarker discovery to the next level.”

Gaining insights on the immune system to support personalized drug development

Immunopeptides play an essential role in the immune system and can be analyzed to support the development of personalized treatments. Mass spectrometry is currently the only technology that can reliably measure and identify immunopeptide profiles of biological samples on a large scale. Biognosys will present their immunopeptidomics workflow, optimized to provide deep and comprehensive biological insights on the immune system in large-scale clinical studies.

Turning data to insights with Spectronaut™, SpectroMine™, and SpectroDive™

Biognosys provides leading software products for proteomics data analysis. In a series of talks, their team will detail how they leverage the latest developments in Machine Learning and Deep Learning to allow deeper insights into the proteome. Biognosys is also excited to host two breakfast seminars with three guest speakers sharing their latest results from using Spectronaut in their research projects. In addition, a sneak-peak into the next planned release will be disclosed.

Gary Kruppa, Vice President, Proteomics at Bruker Daltonics:
“Biognosys’ software tools are among the top solutions for the analysis of proteomics data generated with Bruker instruments. Particularly the latest Spectronaut version yields spectacular performance improvements for dia-PASEF data. We invite all Bruker users to experience Spectronaut’s capabilities and enjoy the exceptional support Biognosys provides.”

Visit biognosys.com/asms2021 for a complete overview of Biognosys’ presence at ASMS.

About Biognosys

Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact Biognosys
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tillotts Pharma AG announces that DIFICLIR TM (fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID8.12.2021 01:01:00 CET | Press release

Tillotts Pharma AG (“Tillotts”), part of the Japanese Zeria Group, welcomes the recommendation that DIFICLIRTM (fidaxomicin) should be used for the initial treatment and first recurrence of Clostridioides difficile infection(CDI) in updated guidance from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).1 ESCMID guidance is now consistent with the Infectious Disease Society of America (IDSA) guidelines which also recommend fidaxomicin for initial and recurrent episodes of CDI.1,2 In one clinical trial the rates of clinical cure with fidaxomicin were noninferior to those with vancomycin (88.2% with fidaxomicin and 85.8% with vancomycin).3 Significantly fewer patients in the fidaxomicin group than in the vancomycin group had a recurrence of the infection (15.4% vs. 25.3%, P=0.005).3 Clinical cure noninferiority was also demonstrated in a separate trial (87.7% with fidaxomicin and 86.8% with vancomycin).4 In this trial similar outcomes were seen in the modifie

NCEC and OURAY Announce Integrated Emergency Response Support for the Global Market8.12.2021 01:01:00 CET | Press release

NCEC, the chemical experts arm of the Ricardo Group, is partnering with OURAY, a global environmental, engineering, manufacturing, and chemical services company, to offer Level One emergency response to OURAY customers, with an emphasis on the Americas and Asia-Pacific regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005770/en/ The National Chemical Emergency Centre (NCEC) (Photo: Business Wire) OURAY’s customers will receive vital telephone-based advice from the experienced NCEC team in the event of a chemical emergency. The agreement underpins the APAC Emergency Response initiative, which is due to start in January from OURAY’s new Singapore base, to provide a chemical response service for the Asia-Pacific region. The telephone emergency response (Level 1) will be carried out by NCEC’s best-in-class emergency response service. The on-site expert advice (Level 2) and the on-ground responder (Level 3) service wi

NTT: Over 80% of CIOs and Senior Leaders Plan to Deploy Private 5G Networks Within the Next 24 Months8.12.2021 01:00:00 CET | Press release

NTT Ltd., a global technology and business solutions provider, is releasing a new report developed by Economist Impact. The report, ‘Private 5G here and now’, reveals insights from a survey of 216 CIOs and senior decision-makers from the UK, US, Japan, and Germany, examining the industry challenges around the implementation and adoption of private 5G. The report shows a significant interest in private 5G networks, with 90% of executives expecting that private 5G will become the standard network choice. Where is private 5G being deployed? The research shows that just over half of companies (51%) planning to deploy a private 5G network will do so within the next six to 24 months to improve security, reliability, and speed, with 30% of these respondents already deploying or being in the process of deploying a private 5G network. The most significant interest is from German organizations, with 40% of German businesses deploying private 5G networks. This is followed by 28% of UK firms, 26%

International Food & Beverage Companies Commit to Further Salt Reduction Globally8.12.2021 00:01:00 CET | Press release

Members of the International Food & Beverage Alliance (IFBA) have developed the first-ever collective commitment by the food industry to implement globally set standardized targets for sodium reduction in manufactured foods. In a letter to World Health Organization Director-General Dr Tedros Adhanom Ghebreyesus, IFBA members pledged to reduce sodium in their global portfolios by 2025 and 2030 in key categories of products that are frequently consumed and are important contributors to sodium intakes within their respective categories. Reducing sodium intake is a key global public health priority identified by the WHO as a measure to help promote a healthy diet and accelerate progress towards achieving several of the global NCD targets and Sustainable Development Goals. The IFBA Global Sodium Reduction Commitment aims to support these goals and builds on members’ significant individual progress to reduce sodium in consumers’ diets over the last two decades. We support the WHO’s Global Ac

Nornir secures €30 Million capital commitment from Global Emerging Markets (GEM)7.12.2021 23:09:00 CET | Press release

The Norwegian deep tech company Nornir, today announced a $30 Million investment commitment from GEM Global Yield LLC SCS (“GEM”), the $3.4 Billion, Luxembourg based, private alternative investment group that focuses on emerging markets with offices in Paris, Nassau (Bahamas) and New York. Under the agreement, GEM will provide Nornir with a Share Subscription Facility of up to €30 Million for a 36 month term following the public listing of the Nornir common stock. Nornir will control the timing and maximum amount of each drawdown under the facility and has no minimum subscription obligation. Nornir's unique “Hive Mind” network technology operates in the AI driven Smart City and smart asset management industry; which is one of the fastest growing markets in the world expected to reach $100 trillion in 2021. The industry is morphing into the Internet of Things (IoT) era which opens up new markets and opportunities where digital assets become intelligent and embedded into various addition

Wordley Partnership: New Partner Appointments Bolster Insurance, Commercial Litigation, International Arbitration and Corporate Practice7.12.2021 20:49:00 CET | Press release

International law firm Wordley Partnership has appointed two new partners, Costas Frangeskides and Simon Schindler. The appointments boost Wordley Partnership’s Insurance sector and Commercial groups. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207006028/en/ Costas Frangeskides (Photo: Business Wire) Brief biographies are enclosed below: Costas is based in London and joins from leading international practice Holman Fenwick Willan (HFW) where he had been a partner since 2002 and is highly experienced in insurance and reinsurance disputes, commercial law, and international arbitration. He has a proven track record and has handled many high-profile commercial and insurance disputes. Commenting on the appointments, managing partner Paul Wordley of Wordley Partnership said: "We are delighted to announce Costas and Simon joining our team. This demonstrates our continuing commitment and expertise in the insurance markets, and

New Data Reveals Social Presence and Engagement Key to Streaming Growth7.12.2021 19:42:00 CET | Press release

Roughly 80% of social engagement for streaming platforms comes from Instagram, with TikTok close behind thanks to accounts like Netflix growing by more than a million followers each month in 2021. This is according to the Social Guide for Streaming report from Conviva, the continuous measurement platform for streaming media, which examined social engagement for more than 87 global streaming platforms and 695 streaming TV shows from January 1, 2021 to October 21, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005982/en/ Conviva’s State of Streaming: Social Guide for Streaming 2021 Publishers Report (Graphic: Business Wire) “A strong presence on social platforms like Facebook, Twitter and Instagram is critical for streaming publishers as it has been proven social is a key to content discovery,” said Keith Zubchevich, CEO, Conviva. “And, it’s not just about posting volume. The publishers that creatively and regularl

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom